Kyowa Kirin to Present New Research Spotlighting Global Efforts to Advance Science and Patient Care in X-linked Hypophosphatemia at ASBMR Annual Meeting

Core Insights - Kyowa Kirin will present new research on burosumab treatment for X-linked hypophosphatemia (XLH) at the ASBMR 2024 annual meeting, highlighting real-world experiences and the disease's impact on patients [1][3] Research Presentation Details - An oral presentation titled "Patient reported outcomes (PRO) from a real-world study of burosumab treatment in adults with X-linked hypophosphatemia in the UK" will be delivered by Judith Bubbear, MD, on September 28 [2] - Multiple poster presentations will cover various aspects of burosumab's effectiveness and patient experiences, including comparisons with conventional therapy and biochemical measurements [4][5] Disease Overview - X-linked hypophosphatemia is a rare genetic disease characterized by low phosphorus levels, leading to bone and muscle issues in both children and adults [6] - The condition results from excess production of fibroblast growth factor 23 (FGF23), causing the body to excrete too much phosphorus [6] Treatment Information - CRYSVITA (burosumab) is a monoclonal antibody that inhibits FGF23, helping to restore phosphorus reabsorption in the kidneys and enhance vitamin D production [7][8] - It is indicated for the treatment of XLH in patients aged 6 months and older [8] Company Background - Kyowa Kirin is a Japan-based global specialty pharmaceutical company focused on drug discovery and biotechnology innovation, with over 70 years of experience [20]